Yoshiyuki Narahara Selected Research

Transjugular Intrahepatic Portasystemic Shunt

8/2014	Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites.
5/2013	Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension.
1/2011	Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
3/2009	[Transjugular intrahepatic portosystemic shunt for refractory ascites: results in 50 patients].
11/2004	Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
5/2002	[Long-term efficacy of transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites].
11/2001	A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiyuki Narahara Research Topics

Disease

6	Fibrosis (Cirrhosis) 12/2014 - 11/2001
6	Ascites 08/2014 - 05/2002
4	Liver Cirrhosis (Hepatic Cirrhosis) 08/2014 - 11/2004
4	Chronic Hepatitis C 07/2014 - 01/2013
3	Edema (Dropsy) 06/2016 - 01/2012
3	Portal Hypertension 02/2014 - 11/2004
2	Varicose Veins (Varicose Vein) 05/2013 - 01/2013
2	Hepatorenal Syndrome 03/2012 - 11/2009
2	Hepatic Encephalopathy 01/2011 - 11/2004
1	Angiodysplasia 05/2013
1	Rectal Neoplasms (Rectal Cancer) 12/2011
1	Liver Diseases (Liver Disease) 12/2011
1	Disease Progression 11/2004
1	Hydrothorax 06/2003
1	Brain Diseases (Brain Disorder) 05/2002
1	Hemorrhage 11/2001

Drug/Important Bio-Agent (IBA)

4	Ribavirin (Virazole)FDA LinkGeneric 12/2014 - 01/2013
3	InterferonsIBA 12/2014 - 01/2013
3	Capsules (Microcapsules)IBA 05/2013 - 02/2011
3	AlbuminsIBA 03/2012 - 01/2011
2	CreatinineIBA 08/2014 - 01/2011
2	Fluvastatin FDA Link 07/2014 - 01/2013
2	TerlipressinIBA 03/2012 - 11/2009
1	DiureticsIBA 06/2016
1	Tolvaptan FDA Link 06/2016
1	Calcifediol (Calcidiol)FDA Link 12/2014
1	telaprevirIBA 07/2014
1	fasudil (AT 877)IBA 02/2014
1	InterleukinsIBA 03/2013
1	Interferon-alpha (Interferon Alfa)IBA 03/2013
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2013
1	AmmoniaIBA 01/2013
1	alfacalcidolIBA 01/2013
1	SteroidsIBA 12/2011
1	Proteins (Proteins, Gene)FDA Link 12/2011
1	N 30IBA 01/2011
1	BilirubinIBA 01/2011
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 11/2004
1	Octreotide (Sandostatin)FDA LinkGeneric 10/2004

Therapy/Procedure

8	Surgical Portasystemic Shunt (Portosystemic Shunt) 08/2014 - 11/2001
7	Transjugular Intrahepatic Portasystemic Shunt 08/2014 - 11/2001
6	Therapeutics 12/2014 - 12/2011
1	Sclerotherapy 11/2001